Women's Precision Medicine 60-Pillar Expansion·Global·Policy — L63~L74 Summer 2026 Second Cycle

L63 through L74 = 22 cycles. 60 pillars 13 dimensions. Summer season second cycle. L74’s 5 topics all expansion·global·policy direction — migraine cognitive visualization, AAD system combination, 15-year policy gap resolution, new ingredient policy, endometriosis diagnostic equity. Precision medicine expanding to policy and global gap resolution.

L63~L74 = 60 Pillars

Accumulated 21 cycles (L63~L73): 55 pillars 12 dimensions

L74 (cycle 22) expansion·global·policy 5:

VYEPTI AAN 2026 INFUSE — migraine cognitive measurement (global 30 countries)
AAD 2026 — atopic·psoriasis system combination (JAK·IL-23·GLP-1)
Tonmya — fibromyalgia 15-year policy gap resolution (80% women)
GHK-Cu 503A compounding legalization — new ingredient policy
Endometriosis 99mTc-maraciclatide — 7~10 year diagnosis delay policy

L63~L74 = 60 pillars.

L74 Meaning — Expansion·Global·Policy

All 5 axes policy·global gap:

1. Pain Measurement Expansion (VYEPTI INFUSE): Headache days → cognitive burden measurement, global 30 countries real-world, individual impact quantified

2. Single Target → System Combination (AAD 2026): IL-17 (skin) + GLP-1 (weight·diabetes), comorbidity integrated care, L66 GLP-1 + L74 IL-17 = multi-axis

3. 15-Year Policy Gap (Tonmya): Fibromyalgia 15-year drug absence, US 10M·80% women, policy gap first drug

4. New Ingredient Policy (GHK-Cu 503A): Cosmetic → drug entry, compounding legalization, medical-grade access

5. Diagnosis Policy (Endometriosis 99mTc): 7~10 year diagnosis delay, 190M global, noninvasive molecular imaging

60 Pillars 13 Dimensions Matrix

Dim 1~~12 (L63~~L73): Drug·environment·diagnosis·new target·daily·fusion·granular·system·visualization·blind spots·digital verification·establishment·next step (55 pillars)

Dim 13 - Expansion·Global·Policy (L74):

Migraine cognitive measurement
System combination (skin+weight)
Policy gap resolution
New ingredient policy
Diagnostic policy

Total 60 pillars 13 dimensions

L74 5-Axis Policy Dimension

1. VYEPTI INFUSE — Measurement Expansion: AAN 2026 (2026.4.20), 30+ countries real-world, cognitive symptoms (brain fog·attention), women 3x chronic pain

2. AAD 2026 — System Combination: Nemolizumab pediatric expansion (2~11), 3 oral drugs (icotrokinra·zasocitinib·envudeucitinib), Ixekizumab + Tirzepatide (skin+obesity)

3. Tonmya — 15-Year Policy Gap: 2025.11 FDA approval, n=1,474 Phase 3, cyclobenzaprine sublingual, US 10M·80% women

4. GHK-Cu — Compounding Legalization: 2026.2 503A legalized, doctor prescription + pharmacist preparation, medical-grade 2~4%, cosmetic → drug entry

5. Endometriosis 99mTc — Diagnostic Policy: Lancet 2026, Oxford × Serac, 7 Phase 2/3 US trials, 7~10 year diagnosis delay resolution

13 Dimensions - Policy Integration

Women’s precision medicine = 13 faces:

Diagnostic·Measurement (5 axes): PGx·microbiome·hormones·methylation·AI pathology + 99mTc endometriosis (L74)

Drug·Pharmacology (7 axes): Targeted·psychedelic·neurostimulation·SARM·DTx·CRISPR + anti-CGRP·system combination·new policy drugs (L74)

Daily·Tools (4 axes): Wearables·nutrition·exercise·meditation

Procedure·OTC (5 axes): Procedures·OTC·self·regeneration·compounding (L74)

Sensory Organs (3 axes): Vision·hearing·pain measurement (L74)

Policy·Access (1 axis, L74): Policy gap·diagnosis delay·new ingredient legalization

Spring~Summer 2026 Flow

Spring 2026 (L63~L72): Discovery·system·visualization·blind spots·digital establishment (50 pillars 11 dimensions)

Summer 2026 (L73~):

L73 Next Step: Self-management·CRISPR·AI official·regeneration·sensory organs (55 pillars 12 dimensions)
L74 Expansion·Global·Policy: Policy gap·system combination·policy dimension (60 pillars 13 dimensions)

L75~L80 expected: Integration·establishment·new areas (nutrition·exercise·women-specific drugs·environment)

Global·Korea Time Gap - L74

US (leading): VYEPTI 30+ countries launch, AAD 2026 drug pipeline, Tonmya FDA approved (2025.11), GHK-Cu 503A legalization (2026.2), 99mTc-maraciclatide Phase 2/3 progressing

Korea adoption: VYEPTI already available·INFUSE data application, AAD drugs 2027~~2028, Tonmya 2027, compounding policy review 2027~~, 99mTc-maraciclatide 2029~2031

Action Guide - 60-Pillar Daily

Migraine patients: Headache diary (app), anti-CGRP options (VYEPTI·other) doctor consult, report cognitive symptoms too

Atopic·Psoriasis patients: Single treatment → system combination consult, comorbid obesity·diabetes evaluation

Fibromyalgia patients: Rheumatology·pain clinic, Lyrica·Cymbalta or Tonmya (post-adoption) options, exercise·sleep·CBT essential

Skin anti-aging: 30s retinol → 40s GHK-Cu → 50s collagen III → 60s senolytic, US compounding possible

Endometriosis suspicion: OB-GYN immediate, ultrasound·MRI → future 99mTc noninvasive, L64 ENDO-205 non-hormonal drug monitoring

Policy Meaning - L74 Message

Women’s precision medicine new stage:

Drug·diagnosis precision = 50 pillars
Next step entry = 55 pillars
Policy·global·access = 60 pillars

Policy gap resolution: 15-year policy gap (fibromyalgia), 7~10 year diagnosis delay (endometriosis), cosmetic limits (compounding legalization), global racial·environmental data

Patient empowerment: Precision medicine = doctor + AI + compounding + global, Korea → global time gap awareness, policy change monitoring

L75~ Preview

Summer season follow-up potential areas: Menopause standard drugs (NEAT·tibolone), pregnancy follow-up monitoring, AI imaging diagnostic follow-up, exercise precision medicine, environmental exposure measurement (PFAS·microplastics)

Conclusion

L74 = 55 pillars → 60 pillars. Expansion·global·policy dimension added. L63~L74 = 60 pillars 13 dimensions. VYEPTI measurement expansion·AAD system combination·Tonmya 15-year policy·GHK-Cu compounding·99mTc diagnostic policy = policy·gap resolution multi-axis. Precision medicine expanding to policy and global gap resolution. Spring complete → summer second cycle. One person’s decisions integrated across 60 pillars 13 dimensions.